Panaccione R, Danese S, Zhou W, Klaff J, et al. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 2023 Nov 27. doi: 10.1111/apt.17816.
PMID: 38010661